Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
EAST RUTHERFORD, N,J., Feb. 02, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2017 financial results will be released on Thursday, February 8, 2018 before the market opens.
The Company will host a conference call to discuss the financial results.
| Fourth Quarter 2017 Earnings Conference Call | |
| When: | Thursday, February 8, 2018 at 8:30 a.m. Eastern Time |
| Dial-in: | 1-888-394-8218 for U.S. |
| 1-323-701-0226 for International | |
| Passcode: 9709552 | |
| Dial-in Replay: | 1-888-203-1112 for U.S. |
| 1-719-457-0820 for International | |
| Passcode: 9709552 | |
| Available through Thursday, February 15, 2018 | |
| Webcast: | www.cambrex.com |
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
Investor Relations Associate
Tel: 201-804-3037
Email: [email protected]
